Sorafenib: atypical cutaneous side effects.
Richetta
Antonio Giovanni
AG
Policlinico Umberto, Viale del Policlinico, 155 - 00161, Rome, Italy. antoniorichetta@hotmail.com
Maiani
Elisa
E
Carboni
Valentina
V
Carlomagno
Valentina
V
Cimillo
Manuella
M
Mattozzi
Carlo
C
Calvieri
Stefano
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000473:pathology; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D020930:MAP Kinase Kinase Kinases